Overview

18F-FSPG PET/CT for Cancer Patients on Therapy

Status:
Completed

Trial end date:
2016-12-14

Target enrollment:

Participant gender:

Summary

The goal of this phase 2 study trial is to evaluate the utility of the radiolabel 18F-FSPG used before and after treatment to diagnose, predict, and evaluate response to therapy in patients with a wide variety of metastatic cancers.

Phase:

Phase 2

Details

Lead Sponsor:

Andrei Iagaru

Collaborator:

National Cancer Institute (NCI)

Treatments:

Fluorodeoxyglucose F18